Avant begins Phase IIb study of TP10 in high-risk infants

AVAN began placebo-controlled U.S. Phase IIb testing of its TP10 complement inhibitor in 30 infants undergoing cardiopulmonary bypass. AVAN hopes to begin a Phase III trial of TP10 infants later this ...